Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
622
mi
from 43215
St. Paul, MN
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
622
mi
from 43215
St. Paul, MN
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
1284
mi
from 43215
Santa Fe, NM
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
1284
mi
from 43215
Santa Fe, NM
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
482
mi
from 43215
Bronx, NY
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
490
mi
from 43215
Poughkeepsie, NY
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
490
mi
from 43215
Poughkeepsie, NY
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
302
mi
from 43215
Asheville, NC
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
302
mi
from 43215
Asheville, NC
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
312
mi
from 43215
Statesville, NC
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
312
mi
from 43215
Statesville, NC
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
2026
mi
from 43215
Portland, OR
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
2026
mi
from 43215
Portland, OR
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
619
mi
from 43215
Providence, RI
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
619
mi
from 43215
Providence, RI
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
991
mi
from 43215
Houston, TX
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
991
mi
from 43215
Houston, TX
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
10147
mi
from 43215
Adelaide,
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
10147
mi
from 43215
Adelaide,
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
331
mi
from 43215
Nashville, TN
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
1969
mi
from 43215
Downey, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
1969
mi
from 43215
Downey, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
1964
mi
from 43215
Pasadena, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
1964
mi
from 43215
Pasadena, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
4501
mi
from 43215
Honolulu, HI
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
4501
mi
from 43215
Honolulu, HI
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
643
mi
from 43215
Boston, MA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
164
mi
from 43215
Ann Arbor, MI
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
721
mi
from 43215
Lincoln, NE
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
721
mi
from 43215
Lincoln, NE
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
1063
mi
from 43215
Cedar Creek, TX
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
1063
mi
from 43215
Cedar Creek, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Site Reference ID/Investigator# 133172
mi
from 43215
Concord,
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Site Reference ID/Investigator# 133172
mi
from 43215
Concord,
Click here to add this to my saved trials
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Status: Enrolling
Updated:  2/22/2017
Brooke Army Medical Center
1135
mi
from 43215
Fort Sam Houston, TX
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Status: Enrolling
Updated: 2/22/2017
Brooke Army Medical Center
1135
mi
from 43215
Fort Sam Houston, TX
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
2108
mi
from 43215
San Franciso, CA
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
2108
mi
from 43215
San Franciso, CA
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Children's Hospital National Medical Center
327
mi
from 43215
Washington,
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Children's Hospital National Medical Center
327
mi
from 43215
Washington,
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
University of Southern Florida College of Medicine
832
mi
from 43215
Tampa, FL
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
University of Southern Florida College of Medicine
832
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Chronic Hepatitis Intervention Project for Drug Users
Chronic Hepatitis Intervention Project for Drug Users
Status: Enrolling
Updated:  2/28/2017
RTI International Field Site
360
mi
from 43215
Durham, NC
Chronic Hepatitis Intervention Project for Drug Users
Chronic Hepatitis Intervention Project for Drug Users
Status: Enrolling
Updated: 2/28/2017
RTI International Field Site
360
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Birmingham Gastroenterology Associates P.C.
495
mi
from 43215
Birmingham, AL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Birmingham Gastroenterology Associates P.C.
495
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Kirklin Clinic
492
mi
from 43215
Birmingham, AL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Kirklin Clinic
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Anaheim Clinical Trials, LLC
1960
mi
from 43215
Anaheim, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Anaheim Clinical Trials, LLC
1960
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
VA Long Beach Healthcare System
1972
mi
from 43215
Long Beach, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
VA Long Beach Healthcare System
1972
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
VA Greater Los Angeles Healthcare System
1982
mi
from 43215
Los Angeles, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
VA Greater Los Angeles Healthcare System
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
University Of California, San Francisco/Sf General Hospital
2107
mi
from 43215
San Francisco, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
University Of California, San Francisco/Sf General Hospital
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Orlando Va Medical Center
792
mi
from 43215
Orlando, FL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Orlando Va Medical Center
792
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Orlando Clinical Research Center
798
mi
from 43215
Orlando, FL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Orlando Clinical Research Center
798
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Infectious Disease Research Institute, Inc.
831
mi
from 43215
Tampa, FL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Infectious Disease Research Institute, Inc.
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Gastrointestinal Specialists of Georgia
425
mi
from 43215
Marietta, GA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Gastrointestinal Specialists of Georgia
425
mi
from 43215
Marietta, GA
Click here to add this to my saved trials